小型非编码RNA作为诊断，预后和预测性生物标志物的妇科癌症：更新
Small non-coding RNAs as diagnostic, prognostic and predictive biomarkers of gynecological cancers: an update
影响因子:3.60000
分区:医学3区 / 病理学3区
发表日期:2024 Nov
作者:
Marios A Diamantopoulos, Panagiotis G Adamopoulos, Andreas Scorilas
摘要
非编码RNA（NCRNA）包含一个异质的RNA分子簇。新兴的证据表明，它们参与了肿瘤发生的各个方面，特别是在妇科恶性肿瘤中。值得注意的是，NCRNA被与肿瘤信号通路中的介体有关，通过与RNA或蛋白质的相互作用来发挥其影响。 These findings further highlight the hypothesis that ncRNAs constitute therapeutic targets and point out their clinical potential as stratification biomarkers.The review outlines the use of small ncRNAs, including miRNAs, tRNA-derived small RNAs, PIWI-interacting RNAs and circular RNAs, for diagnostic, prognostic, and predictive purposes in gynecological cancers.它的目的是提高我们对肿瘤生物学功能的了解及其转化为临床实践。通过利用跨学科合作，科学家可以将小型NCRNA生物标志物的谜语解密为妇科肿瘤的诊断，预后和预测性生物标志物。将基于NCRNA的小测定纳入临床实践将使临床医生可以为每个患者提供治疗计划，从而降低不良反应的可能性。然而，应对诸如标准化实验方法和精炼诊断测定等挑战对于推进妇科癌症中的小型NCRNA研究至关重要。
Abstract
Non-coding RNAs (ncRNAs) comprise a heterogeneous cluster of RNA molecules. Emerging evidence suggests their involvement in various aspects of tumorigenesis, particularly in gynecological malignancies. Notably, ncRNAs have been implicated as mediators within tumor signaling pathways, exerting their influence through interactions with RNA or proteins. These findings further highlight the hypothesis that ncRNAs constitute therapeutic targets and point out their clinical potential as stratification biomarkers.The review outlines the use of small ncRNAs, including miRNAs, tRNA-derived small RNAs, PIWI-interacting RNAs and circular RNAs, for diagnostic, prognostic, and predictive purposes in gynecological cancers. It aims to increase our knowledge of their functions in tumor biology and their translation into clinical practice.By leveraging interdisciplinary collaborations, scientists can decipher the riddle of small ncRNA biomarkers as diagnostic, prognostic and predictive biomarkers of gynecological tumors. Integrating small ncRNA-based assays into clinical practice will allow clinicians to provide cure plans for each patient, reducing the likelihood of adverse responses. Nevertheless, addressing challenges such as standardizing experimental methodologies and refining diagnostic assays is imperative for advancing small ncRNA research in gynecological cancer.